Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axicabtagene Ciloleucel in R/R HIV-Associated Aggressive B-Cell NHL
NCT05077527Phase 1Recruiting
- Sponsor
- AIDS Malignancy Consortium
- Start
- Feb 2025
- Primary completion
- Jan 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of axicabtagene ciloleucel in aggressive B cell non-Hodgkin lymphoma, sponsored by AIDS Malignancy Consortium. Primary endpoints: Safety of chimeric antigen receptor (CAR) T-cell therapy at 2 years and Feasibility of CAR-T Therapy at 2 years. Started Feb 2025; status: recruiting.
02
Drugs
axicabtagene ciloleucel
03
Conditions
aggressive B cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05077527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05077527.